Arcutis Biotherapeutics Inc ARQT:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:47 PM EDT
9.06quote price arrow down-0.18 (-1.95%)
Volume
86,401
Close
9.24quote price arrow up+1.11 (+13.65%)
Volume
12,745,670
52 week range
1.76 - 13.17
Loading...
  • Open9.42
  • Day High10.13
  • Day Low8.90
  • Prev Close8.13
  • 52 Week High13.17
  • 52 Week High Date04/09/24
  • 52 Week Low1.76
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap1.067B
  • Shares Out115.53M
  • 10 Day Average Volume2.69M
  • Dividend-
  • Dividend Yield-
  • Beta1.17
  • YTD % Change186.07

KEY STATS

  • Open9.42
  • Day High10.13
  • Day Low8.90
  • Prev Close8.13
  • 52 Week High13.17
  • 52 Week High Date04/09/24
  • 52 Week Low1.76
  • 52 Week Low Date12/01/23
  • Market Cap1.067B
  • Shares Out115.53M
  • 10 Day Average Volume2.69M
  • Dividend-
  • Dividend Yield-
  • Beta1.17
  • YTD % Change186.07

RATIOS/PROFITABILITY

  • EPS (TTM)-3.90
  • P/E (TTM)-2.37
  • Fwd P/E (NTM)-3.82
  • EBITDA (TTM)-239.55M
  • ROE (TTM)-175.79%
  • Revenue (TTM)59.606M
  • Gross Margin (TTM)91.63%
  • Net Margin (TTM)-439.79%
  • Debt To Equity (MRQ)227.59%

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arcutis Biotherapeutics Inc

 

Profile

MORE
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in...
Patrick Heron
Independent Chairman of the Board
Todd Watanabe
President, Chief Executive Officer, Director
David Topper
Chief Financial Officer
Address
3027 Townsgate Road, Suite 300
Westlake Village, CA
91361
United States